## nature portfolio

Corresponding author(s):	Denis Evseenko
Last updated by author(s):	November 25, 2021

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Sta	tistics			
For a	all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	(a Confirmed			
	The exact	sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement		
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
$\boxtimes$	A description of all covariates tested			
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.			
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
$\boxtimes$	Estimates	of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated		
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code				
Polic	y information	about <u>availability of computer code</u>		
Da	ta collection	N/A		
Da	ta analysis	N/A		
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				
Dat	ta			
Polic	y information	about <u>availability of data</u>		
All manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable:				
- Accession codes, unique identifiers, or web links for publicly available datasets - A description of any restrictions on data availability				
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>				
scRN	IA-sequencing d	ata will be deposited in GEO under the accession number GSEXXXX		

Field-specific reporting					
Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of t	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life scier	nces study design				
All studies must dis	close on these points even when the disclosure is negative.				
Sample size	Sample sizes were chosen based on empirical observations of size of effect and are stated throughout the manuscript.				
Data exclusions	No data were excluded.				
Replication	All experiments were repeated with multiple litters representing different biological replicates. All data were reproducible.				
Randomization	On Randomization was not necessary for this study based on comparing different genotypes, or where appropriate, treated cells to their own untreated controls.				
Blinding	Blinded observers were used when calculating growth plate measurements, scoring immunohistochemistry and EdU/TUNEL slides.				
Reporting for specific materials, systems and methods					
	on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ted is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & ex	perimental systems Methods				
n/a Involved in th	ne study n/a Involved in the study				
Antibodies	ChIP-seq				
Eukaryotic					
	ogy and archaeology MRI-based neuroimaging				
	d other organisms				
	search participants				
Clinical dat					
X     Dual use re	Dual use research of concern				
Antibodies					
Antibodies used	All antibody information is provided in the 'Materials and Methods' section of the manuscript.				
Validation	Primary antibodies were used based on the species validation information listed on the manufacturers' websites.				
Flow Cytome	sti y				
Plots					
Confirm that:	Confirm that:				
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).					
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).					
All plots are contour plots with outliers or pseudocolor plots.					
A numerical value for number of cells or percentage (with statistics) is provided.					
Methodology					

	$\overline{a}$	۰
	뇓	
	~	
	Ξ	
	α	ì
٠.		
	C	
	Z	
		۱
	$\subseteq$	
	2	
	⋍	
	7	١
	_	۰
-		
	_	
	ā	
	<u>ر</u>	
	<u>_</u>	
	Č	
	Č	
-		
	Č	

March 2021

Software	FlowJo
Cell population abundance	Abundance was not a metric of interest in this study.
Gating strategy	Samples were sorted as negative for lineage markers and live based on unstained controls.